BioStock: Curasight applies for clinical trial of uTREAT for brain cancer
Danish biotech company Curasight has submitted an application to the EMA for clinical trial authorisation to the EMA for a phase I study of uTREAT in patients with glioblastoma. The first patient is expected to receive treatment in the second half of 2025.
Read the full article at biostock.se:
https://biostock.se/en/2025/06/curasight-klinisk-provning-utreat-hjarncancer/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/